Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06501924 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss

StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 19, 2024 (before its estimated October 17, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Study description expanded, about 6 wordsv10
  2. Start date: Nov 15, 2024 to Jan 15, 2025v9
  3. Eligibility criteria revised
    • Study description revised
    v8
  4. Interventions: DA-001 (Dietary Supplement), DA-002 (Drug), Placebo Oral Tablet (Dietary Supplement), Placebo Topical Solution (Other), Topical minoxidil… to DA-002 (Drug), DA-005 (Dietary Supplement), Placebo Oral Tablet (Dietary Supplement), Placebo Topical Solution (Other), Topical minoxidil…
    • Study title revised
    v7
  5. Start date: Sep 16, 2024 to Nov 15, 2024v6 Show 6 more changesShow less
    • Primary completion date: Jul 11, 2025 to Oct 17, 2025
    • Study completion date: Sep 12, 2025 to Dec 12, 2025
    • Interventions: Daniel Alain Botanical Supplement Treatment for Hair Loss (Dietary Supplement), Topical minoxidil 5% (Drug) to DA-001 (Dietary Supplement), DA-002 (Drug), Placebo Oral Tablet (Dietary Supplement), Placebo Topical Solution (Other), Topical minoxidil…
    • Study description expanded, about 40 words
    • Study arms: 2 to 3
    • Study title expanded, about 3 words
Show 4 earlier versionsHide 4 earlier versions
  1. Primary endpoints: 1 to 2v5
  2. Primary completion date: Jul 15, 2025 to Jul 11, 2025
    • Study completion date: Sep 15, 2025 to Sep 12, 2025
    • Start date: Sep 15, 2024 to Sep 16, 2024
    v4
  3. Primary completion date: Mar 15, 2025 to Jul 15, 2025
    • Study completion date: Jun 15, 2025 to Sep 15, 2025
    v3
  4. Collaborators: 1 to 2v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objective of the study is to assess the safety and efficacy of DA-005 and DA-002 as a treatment for hair loss (androgenetic alopecia).
Trial Details
NCT Number NCT06501924
Lead Sponsor Applied Biology, Inc.
Collaborators: Follea International Limited, Daniel Alain, Inc.
Conditions
(from sponsor)		 Androgenetic Alopecia, Female Pattern Baldness, Male Pattern Baldness
Related terms Alopecia
Enrollment 516 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov